Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 2, 2011, Pages 96-102

  Reed, Robert M ^a   Iacono, Aldo ^a   Defilippis, Andrew ^b   Jones, Steven ^b   Eberlein, Michael ^b   Lechtzin, Noah ^b   Girgis, Reda E ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Pulmonary pressures; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY WEDGE PRESSURE; PYRROLES; REGRESSION ANALYSIS; SIMVASTATIN;

EID: 79954545820     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.558545     Document Type: Article

References (56)

1. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107(5):1193-1198.
2. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease.Thorax 1981; 36(10):752-758. (Pubitemid 12249743)
3. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159(1):158-164. (Pubitemid 29036519)
4. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136(2):412-419.
5. MacneeW. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150(3):833-852. (Pubitemid 24291518)
6. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5):892-905. (Pubitemid 36592303)
7. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43(3):183-189. (Pubitemid 18086542)
8. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascularmorbidity. Int J Chron Obstruct Pulmon Dis 2009; 4:337-349.
9. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128(4):2640-2646. (Pubitemid 41507622)
10. Melot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130(4): 612-616. (Pubitemid 15200014)
11. Rietema H, Holverda S, BogaardHJ, Marcus JT, SmitHJ, Westerhof N, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31(4):759-764.
12. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. Eur Respir J 1988; 1(8): 716-720.
13. Stolz D, RaschH, Linka A, Di ValentinoM,Meyer A, BrutscheM, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32(3):619-628.
14. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109(1):7-15.
15. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285(3):H938-H945. (Pubitemid 37048146)
16. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292(5):L1105-L1110. (Pubitemid 47084854)
17. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172(8):987-993.
18. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176(8):742-747. (Pubitemid 47598474)
19. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008; 62(9):1373-1378.
20. Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009; 116(6):497-505.
21. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30(4):458-470.
22. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166(3):314-322. (Pubitemid 34864419)
23. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127(5):1531-1536. (Pubitemid 46218776)
24. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(2):189-194. (Pubitemid 40981192)
25. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, CanuetM, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136(3):678-687.
26. Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008; 14(2):115-121. (Pubitemid 351323162)
27. Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179(1):35-40.
28. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(6): 513-520.
29. Desai A, Fang JC. Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. Heart Fail Clin 2008; 4(1):87-97. (Pubitemid 351291707)
30. Harris P, Segel N, Green I, Housley E. The influence of the airways resistance and alveolar pressure on the pulmonary vascular resistance in chronic bronhcitis. Cardiovasc Res 1968; 2(1):84-92.
31. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002; 11(5):489-496.
32. Ferrier KE,MuhlmannMH, Baguet JP, Cameron JD, JenningsGL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6):1020-1025. (Pubitemid 34234125)
33. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34(6):1281-1286. (Pubitemid 30002395)
34. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, et al.Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits pras activation. Circulation 2002; 106(16):2118-2124. (Pubitemid 35192819)
35. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004; 68(2):121-125. (Pubitemid 38197247)
36. Patel R,Nagueh SF, Tsybouleva N,Abdellatif M, Lutucuta S,Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104(3):317-324. (Pubitemid 32666954)
37. Smilde TJ, Van Den Berkmortel FW,Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000; 30(6):473-480. (Pubitemid 30330459)
38. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by highresolution noninvasive magnetic resonance imaging. Circulation 2002; 106(23):2884-2887. (Pubitemid 35424736)
39. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23 Suppl 1):III39-III43. (Pubitemid 38786442)
40. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18):2356-2363. (Pubitemid 40647072)
41. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272(50):31725-31729. (Pubitemid 28013321)
42. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5):1126-1131. (Pubitemid 27097821)
43. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105(2):213-217. (Pubitemid 34084321)
44. Alpert NR, LeWinter M, Mulieri LA, Hasenfuss G. Chemomechanical Energy Transduction in the Failing Heart. Heart Failure Reviews 1999; 4(3):281-295. (Pubitemid 30153587)
45. Zheng X, Hu SJ. Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 2005; 26(6):696-704. (Pubitemid 40806559)
46. SakaM,Obata K, Ichihara S, ChengXW, Kimata H, Nishizawa T, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47(6):770-779. (Pubitemid 44305251)
47. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest 2008; 134(4):808-814.
48. Matsuoka S, Washko GR, Yamashiro T, Estepar RS, Diaz A, Silverman EK, et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 2010; 181(3):218-225.
49. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, et al. Simvastatin rescues rats fromfatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108(13):1640-1645. (Pubitemid 37187793)
50. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C,Wood K, Tuder RM, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291(4):L668-L676. (Pubitemid 44498478)
51. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographicbased survey of a population sample. Eur Heart J 2003; 24(4):320-328. (Pubitemid 36215965)
52. Samdarshi TE, TaylorHA, EdwardsDQ, Liebson PR, Sarpong DF, Shreenivas SS, et al. Distribution and determinants of Dopplerderived diastolic flow indices in African Americans: the Jackson Heart Study (JHS). Am Heart J 2009; 158(2):209-216.
53. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164(2):219-224. (Pubitemid 34001285)
54. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130(6):993-998. (Pubitemid 15186152)
55. Bishop JM, Cross KW. Use of other physiological variables to predict pulmonary arterial pressure in patients with chronic respiratory disease. Multicentre study. Eur Heart J 1981; 2(6):509-517. (Pubitemid 12167733)
56. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: A systematic review. Chest 2009; 136(3):734-743.